N
Niklas Bergvall
Researcher at Novartis
Publications - 34
Citations - 1274
Niklas Bergvall is an academic researcher from Novartis. The author has contributed to research in topics: Fingolimod & Birth weight. The author has an hindex of 16, co-authored 32 publications receiving 1185 citations. Previous affiliations of Niklas Bergvall include Karolinska Institutet & McGill University Health Centre.
Papers
More filters
Journal ArticleDOI
Risk of High Blood Pressure Among Young Men Increases With the Degree of Immaturity at Birth
Stefan Johansson,Anastasia Iliadou,Niklas Bergvall,Torsten Tuvemo,Mikael Norman,Sven Cnattingius +5 more
TL;DR: The risk of high systolic BP associated with birth weight for GA is modified by GA, suggesting that perinatal contributions to BP elevation later in life may be induced by different biological pathways.
Journal ArticleDOI
Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.
Anders Gustavsson,Per Brinck,Niklas Bergvall,Katarzyna Kolasa,Anders Wimo,Bengt Winblad,Linus Jönsson +6 more
TL;DR: This work aimed to identify what measures of disease severity are the most important predictors of societal costs of care and whether their relationship differs across countries.
Journal ArticleDOI
Genetic and Shared Environmental Factors Do Not Confound the Association Between Birth Weight and Hypertension A Study Among Swedish Twins
Niklas Bergvall,Anastasia Iliadou,Stefan Johansson,Ulf de Faire,Michael S. Kramer,Yudi Pawitan,N. L. Pedersen,Paul Lichtenstein,Sven Cnattingius +8 more
TL;DR: It is found that decreased birth weight is associated with increased risk of hypertension independently of genetic factors, shared familial environment, and risk factors for hypertension in adulthood, including body mass index.
Journal ArticleDOI
Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease
Niklas Bergvall,Per Brinck,Daniel Eek,Anders Gustavsson,Anders Wimo,Bengt Winblad,Linus Jönsson +6 more
TL;DR: For patients residing in community dwellings, the direct influence of patients’ cognition on caregiver burden is limited and rather mediated by other disease indicators, which means both ADL-abilities and behavioral disturbances are important predictors of perceived caregiverurden.
Journal ArticleDOI
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
TL;DR: It is suggested that fingolimod therapy results in a higher probability of NEDA than dimethyl fumarate and teriflunomide therapy when phase 3 trial data are indirectly compared and differences between trials are adjusted for.